6) None Calcineurin inhibitors before conversion to belatacept The study identifies a potentially safe and feasible method for switching stable renal transplant patients from a cyclosporine- or tacrolimus-based regimen to a belatacept-based regimen, which may allow improved renal function in patients currently treated with CNIs
Because some patients were given belatacept at transplantation (de novo patients) whereas others were converted to belatacept mainly because of impaired kidney function and/or histology, and because in some patients belatacept was ceased due to complications Patients receiving cyclosporine or tacrolimus were randomized to switch to belatacept or continue CNI
Given the presumed high risk of rejection, MMF was maximized to 2–3g/day as tolerated on day-1 Belatacept is a novel immunosuppressive agent that may be used as an alternative to calcineurin inhibitors (CNI) in immunosuppression (IS) regimens
When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects
Mean SCr, serum creatinine; UPr/UCr, random urine protein to urine creatinine ratio; BGL, blood glucose levels
There is no literature on the use of belatacept for
Like other studies, eGFR significantly improved over the first 3 months, probably after suspending the hemodynamic effect of CNIs ( 8 , 13 , 14 , 25 ), and remained stable up to year 5 after Patients receiving cyclosporine or tacrolimus were randomized to switch to belatacept or continue CNI
5
7 and 2
Is Belatacept Switch Safe in Renal Transplant Recipients With Donor-specific Antibodies? Süsal, Caner MD 1; Morath, Christian MD 2
In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)–based regimens
(Fc Fragment of IgG Receptor and transporter), and S100A9 were downregulated 3 months after the switch between belatacept and assigned (1:1) to switch to 5 mg/kg of belatacept (intravenous; days 1, 15, 29, 43, and 57 and every 28 days thereafter) or to remain on existing CNI-based therapy, with randomization strati-fied by CNI regimen (cyclosporine or tacrolimus) and site
Only 2 patients remained on low-dose tacrolimus after initiating belatacept because of a history of antibody Belatacept and Outcomes in Kidney Transplantation
When compared to a 1:2 propensity-matched control cohort from the INSERM U970